๐
Gamifant
emapalumab
Immune System Diseases
โ Refused
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/gamifant